Full Text View
Tabular View
No Study Results Posted
Related Studies
Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke (ESS)
This study has been completed.
Study NCT00604630   Information provided by Max-Planck-Institute of Experimental Medicine
First Received: January 17, 2008   Last Updated: October 21, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Infarction, Middle Cerebral Artery
Middle Cerebral Artery Stroke
Stroke, Acute
Additional conditions recognized in this trial
Cerebral Infarction
Infarction
Stroke
More general conditions related to this trial
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebral Arterial Diseases
Cerebrovascular Disorders
Intracranial Arterial Diseases
Ischemia
Necrosis
Nervous System Diseases
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
0.9% NaCl
Additional drug interventions recognized in this trial
Epoetin Alfa
More general drug interventions related to this trial
Hematinics
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Max-Planck-Institute of Experimental Medicine
Johnson &Johnson
Parexel


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services